



Commercial/Healthcare Exchange Step Criteria

Effective: April 2010

Step Therapy Name: Preferred GLP-1 inhibitors (Incretin Mimetics)

Step 1 Agent(s): Cycloset, Acarbose, Glyset, Miglitol, Precose, Fortamet, Glucophage/XR, Glumetza, metformin/ER, Riomet, Oseni, alogliptin-pioglitazone, alogliptin, Januvia, Nesina, Onglyza, Tradjenta, Amaryl, Chlorpropamide, glimepiride, glipizide/XL/ER, Glucotrol/XL, glyburide, Glynase, nateglinide, Prandin, repaglinide, Starlix, tolazamide, tolbutamide, Glyxambi, Qtern, Steglujan, Actoplus Met/XR, Avandamet, pioglitazone-metformin, Duetact, pioglitazone-glimepride, alogliptin-metformin, Janumet/XR, Jentadueto/XR, Kazano, Kombiglyze XR, glipizide-metformin, Glucovance, glyburide-metformin, repaglinide-metformin, Actos, Avandia, pioglitazone, Admelog/Solostar, Afrezza, Apidra, Basaglar, Fiasp, Humalog (all), Humulin (all), Insulin lispro, Lantus, Levemir, Myxredlin, Novolin (all), Novolog (all), Toujeo, Tresiba

Step 2 Agent(s): Bydureon, Byetta, Victoza, Ozempic, Rybelsus

Medication/Class Description:

GLP-1 is produced from the proglucagon gene in L-cells of the small intestine and is secreted in response to food intake. GLP-1 binds to specific GLP-1 receptors expressed in various tissues including pancreatic beta cells, pancreatic ducts, gastric mucosa, etc. GLP-1 exerts its main effect by stimulating glucose-dependent insulin release from the pancreatic islets. It has also been shown to slow gastric emptying, inhibit inappropriate post-meal glucagon release, and thereby reduce food intake. Exenatide administration results in decreases in hemoglobin A1c (HbA1c) by approximately 0.5% to 1% (immediate release) or 1.5% to 1.9% (ER). Liraglutide administration results in decreases in hemoglobin A1c by approximately 1%. Due to the effects of GLP-1 on slowed gastric emptying and appetite centers in the brain, therapy with GLP-1 receptor agonists is associated with weight loss, even among patients without significant nausea and vomiting.

Required Medical Information:

1. History of previous therapy tried/failed
2. Current therapy regimen
3. Hgb A1C value(s)

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Exceptions for Stepped Medications

1. Member has history of failure of a Step 1 agent, defined as:
 - a. Failure to decrease Hemoglobin A1C; **OR**
2. Member has intolerance to a Step 1 agent, defined as (but not limited to):
 - a. Allergic reaction; **OR**
 - b. Adverse drug reactions; **OR**
3. Member is currently stable on Step 2 agent; **AND**

Last Res.12.9.2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

4. Change in therapy deemed medically unsafe, defined as (but not limited to):
 - a. High potential for bodily harm; **OR**
 - b. High potential for poor therapeutic outcomes

References:

1. Product Information: TANZEUM(TM) subcutaneous injection, albiglutide subcutaneous injection. GlaxoSmithKline (per FDA), Research Triangle Park, NC, 2015.
2. Product Information: TRULICITY(TM) subcutaneous injection, dulaglutide subcutaneous injection. Eli Lilly and Company (per manufacturer), Indianapolis, IN, 2014.
3. Product Information: Victoza(R) subcutaneous injection solution, liraglutide rDNA origin subcutaneous injection solution. Novo Nordisk Inc. (per FDA), Plainsboro, NJ, 2015.
4. Product Information: BYDUREON(R) subcutaneous extended-release injection suspension, exenatide subcutaneous extended-release injection suspension. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2015.
5. Product Information: BYETTA(R) subcutaneous injection, exenatide subcutaneous injection. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2015.
6. Product Information: ADLYXIN subcutaneous injection, lixisenatide subcutaneous injection. Sanofi-Aventis (per FDA), Bridgewater, NJ, 2016
7. Product Information: OZEMPIC(R) subcutaneous injection, semaglutide subcutaneous injection. Novo Nordisk Inc (per manufacturer), Plainsboro, NJ, 2017.
8. Product Information: RYBELSUS(R) oral tablets, semaglutide oral tablets. Novo Nordisk Inc (per manufacturer), Plainsboro, NJ, 2019.

Revision History:

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	Update	New Template; Addition of Rybelsus CCI P&T Review History: 4/10, 9/10, 12/10, 12/11, 10/12, 10/13, 11/15, 2/16, 11/16, 2/17, 5/17, 5/18, 5/19 CCI Revision Record: 12/10, 3/12, 11/12, 4/14, 6/14, 11/14, 11/16, 2/17, 5/17, 1/18, 5/18, 5/19	All	12/9/2019